GoodRx Holdings, Inc. - GDRX STOCK NEWS

GoodRx Holdings, Inc. (NASDAQ: GDRX) has appointed Scott Wagner, former CEO of GoDaddy, as its Interim CEO, effective April 25, 2023. Co-founders Doug Hirsch and Trevor Bezdek will transition to roles as Chief Mission Officer and Chairman, respectively. Wagner brings over 25 years of experience and aims to enhance product innovation and customer base growth. With his leadership, GoodRx aims to improve healthcare accessibility and affordability, having helped Americans save over $55 billion on medications. Hirsch will continue to focus on operationalizing the company's mission, while Bezdek will guide healthcare strategy and innovation. An update for investors is anticipated during the earnings call on May 10.

GoodRx Holdings, Inc. (GDRX) will release its Q1 2023 financial results before U.S. markets open on May 10, 2023. A conference call is scheduled for 5:00 a.m. Pacific Time to discuss the results and business outlook. GoodRx, a leading digital healthcare platform, provides consumers with access to lower prices for medications and telehealth consultations. Since its inception in 2011, GoodRx has helped individuals save over $55 billion on healthcare costs. The earnings call will be accessible online, and an archived version will be available for 30 days post-call.

GoodRx Holdings, Inc. (Nasdaq: GDRX) reported its fourth quarter and full-year 2022 financial results, exceeding previous guidance. Q4 2022 revenue was $184.1 million, a 14% decline year-over-year, with a net loss of $2.01 million. Adjusted net income for Q4 stood at $27.4 million. Annual revenue was $766.6 million with a net loss of $32.81 million. Prescription transactions revenue fell 19% due to an 8% drop in Monthly Active Consumers and continued grocer-related issues, estimated to impact revenue by $40-$50 million. Future guidance for Q1 2023 projects revenue of $181-$183 million, reflecting ongoing challenges.

GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading digital healthcare platform, will present at the Cowen 43rd Annual Health Care Conference in Boston, MA, on Tuesday, March 7, 2023, at 6:50 a.m. Pacific Time (9:50 a.m. Eastern Time). A live webcast of the presentation can be accessed through the Company’s investor relations website at https://investors.goodrx.com/, with an archived recording to be available for 30 days afterward. GoodRx has been committed to making healthcare affordable, saving consumers over $45 billion since 2011, and remains one of the most downloaded medical apps in the past decade.

GoodRx Holdings Inc. (NASDAQ: GDRX) will report its fourth quarter and full year 2022 financial results on February 28, 2023, after U.S. markets close. A conference call is scheduled for 2:00 p.m. PT (5:00 p.m. ET) to discuss these results and provide insights into the company’s future outlook. Investors can pre-register for the call and access a live webcast through GoodRx's investor relations website. Since 2011, GoodRx has saved consumers over $45 billion, offering affordable medication prices and telehealth services.

GoodRx Holdings, Inc. (Nasdaq: GDRX), a top digital healthcare platform, is set to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 11, 2023, at 3:45 p.m. PT. A live webcast of this presentation will be available on the Company's Investor Relations website and will be archived for 30 days. GoodRx has saved consumers over $45 billion since its inception in 2011, providing affordable healthcare solutions to Americans.

GoodRx Holdings, Inc. (GDRX) has reported its third-quarter 2022 financial results, achieving total revenue of $187.3 million, which surpassed previous guidance despite a 4% year-over-year decline. The net loss was $41.7 million, reflecting a challenging environment, particularly from the grocer issue affecting prescription transactions revenue, which decreased 16% to $131.2 million. However, subscription revenue grew by 63% to $26.5 million. Adjusted EBITDA was reported at $52.0 million, a decrease from the prior year, with management anticipating fourth-quarter revenue guidance of $175-$180 million, factoring continued challenges.

GoodRx (NASDAQ: GDRX) released a report indicating that expanding pharmacist prescribing authority significantly enhances access to critical medications, especially for PrEP (HIV prevention pill). The report highlights an increase in PrEP fills by 24% after one year and 110% after two years in states that allow pharmacists to prescribe. Over 37 million Americans reside in under-resourced areas where pharmacist authority could enhance healthcare access. GoodRx emphasizes that improved access leads to better medication adherence, benefiting both patients and healthcare providers.